CURRICULUM VITAE 

Rüdiger HEHLMANN, Prof. Dr. med.

Personal Data
Business address: III. Medizinische Universitätsklinik, Klinikum Mannheim, Universität Heidelberg,
Wiesbadener Str. 7-11, 68305 Mannheim, Germany,
Fon: +49-(0)-621-383-4115,
Fax: +49-(0)-621-383-4201,
E-Mail: R.Hehlmann@urz.uni-heidelberg.de
Married to: Dr. Annemarie Hehlmann, four children: Johannes, Karoline, Rüdiger, Corinna
Date and place of birth: May 10, 1941, Halle/Saale, Germany

Education
1961-1966 Study of Medicine at Marburg, Freiburg, Edinburgh, Munich
Graduation: Dec. 1966
Stevenson Exchange Scholar (Edinburgh) 1964-1965
Scholar Studienstiftung des Deutschen Volkes 1963-1969

1967-1969 Internship in Gynecology, Surgery and Medicine, Munich
MD-PhD, Scholar Max Planck Institute for Biochemistry, Munich
MD: 22.7.1969, Approval as Physician 30.06.1969

Academic Career

1969-1970
Assistant, Max Planck Institute for Biochemistry, Munich

1970
Research Fellow, University of Rochester, New York, USA

1970-1972
Research Associate, Columbia University, New York

1972-1973
Lecturer in Human Genetics and Development at Columbia University

1973-1974
Intern/Resident, Columbia-Presbyterian Medical Center
Licence to practice Medicine and Surgery in the State of New York, 16.09.1974

1974
DFG (German Research Council)-stipend, Memorial Sloan Kettering Cancer Center

1974-1981Assistant at the Medizinische Universitätspoliklinik, Munich
Independent research group at the Research Center GSF, Neuherberg

1977
Approval as Internist

1979
Major Postdoctoral Thesis (Habilitation)
Tenured Professor (C2) at Munich University

1982-present
Chairman of the German CML-Study Group

1984
Approval as Hematologist and Oncologist

1988-present
Full Professor of Medicine (C4) at the Mannheim Medical Faculty of the University of Heidelberg and Director of the III. Medizinische Universitätsklinik in Mannheim

1997-present
Chairman of the Competence Network "Acute and Chronic Leukemias"
Dean of the Mannheim Medical Faculty

2003-present
Chairman of the Network of Excellence "European LeukemiaNet"

Career-related Activities

1981-1988
Vice chairman of the Society for Morphology and Physiology, Munich

1984
First AIDS-seroepidemiology in Germany (Lancet 1984)

1986-1996
Editor of the scientific journal "AIDS-Forschung"

1987
Advisor, AIDS-Hearing at the Bavarian Parliament (Bayerischer Landtag)

1987-1988
Advisor to the Enquete Commission on AIDS of the German Parliament (Bundestag)

1989-1991
Delegate (Fachvertreter) of the German Ministry for Research and Technology at the European Commission in Brussels concerning AIDS

1986-1990
Vice chairman of the South-German Hemoblastosis Group (SHG)

1989-present     Member (M.) of the World Committee of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD)

1995-1997
President of the IACRLRD

1996
M. of the advisory committee to the German Government on cost evaluation of clinical university medicine

1997-present
Secretary General of the IACRLRD

1990-present
M. of the Steering Committee of the Cancer Center Heidelberg/Mannheim

1993-1998
M. of the review committee (of the German Ministry for Research and Technology) for funding research on Infectious Diseases

1995-1999
M. of the review committee (of the German Ministry for Research and Technology) for funding research on Public Health

1995-present
M. of the Scientific Advisory Board of the German José Carreras Leukemia Foundation

1996-2000
M. of the CML-Guidelines Committee of the American Society of Hematology

1996-2004
M. of the Advisory Board of the German Society for Hematology and Oncology

1996-present
Section Editor for CML of the journal "Leukemia";
M. of the Editorial Boards of the journals: Annals of Hematology, European Journal of Medical Research

1997-2000
Delegate of the German Society for Hematology and Oncology to the Working Party of Scientific Medical Societies (AWMF)

2000-2001
President of the German Society for Hematology and Oncology

2001-present
M. of the Steering Committee of the German AML Intergroup

2002-present
Cofounder and Chairman of the Leukemia Foundation (in support of the German Leukemia Net)

2005-2006
M. of the Steering Committee of the Interdisciplinary Tumor Center Mannheim (ITM)

Organization of Scientific Meetings

1991-2006
16. International Workshops on CML in Weinheim, Mannheim and Heidelberg

1997, 2005
XIX and XXII Symposium of the IACRLRD in Mannheim and Heidelberg

2001
Annual Congress of the German and Austrian Societies of Hematology and Oncology in Mannheim

2003
11. Annual Meeting of the European Investigators on CML in Berlin

1999-2003
Annual Symposia of the Competence Network "Akute und chronische Leukämien" in Heidelberg

2002-2006
Annual meetings of the European LeukemiaNet in the context of the annual conferences of the American Society of Hematology (ASH)

2004-2006
Annual Combined Symposia of the German and European Leukemia Networks in Heidelberg

Research Interests

- Mechanisms of cacinogenesis (retroviruses, chemicals, environment), mutation-proliferation vs. chromosomal hypotheses

- Diagnosis and therapy of leukemias (CML, chronic myeloproliferative diseases, AML, molecular monitoring,)

- Tyrosinkinase signalling and inhibition, mechanisms of resistance

- Clinical trials in hematology and oncology

Outside financial research support (2005): 3,5 Mio €, two thirds public and foundations 

(EU, BMBF, Krebshilfe, Carreras etc.), one third industry.

Science Awards and Honors

1984
Curt Bohnewand-Prize for scientific cooperation in cancer research

1990
GSF-Prize for interdisciplinary cooperation
Paul Martini-Prize for improvement of prognosis in CML

2004
Guest Professorship at Cornell University, New York, with R.T. Silver-Lecture

2005
Honorary Member of the Polish Society for Hematology and Transfusion Medicine

2006
Wiedermann-Lecture, Olomouc (Olmütz), Czechia

Selected Publications

Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Grießhammer M, Bergmann L, Essers U, Falge C, Queißer U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, von Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, and the German CML Study Group: Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 84:4064-4077 (1994)

Seifarth W, Skladny H, Krieg-Schneider F, Reichert A, Hehlmann R, Leib-Mösch C: Retrovirus-like particles released from the human breast cancer cell line T47-D display type B- and C-related endogenous retroviral sequences. J Virol 69:6408-6416 (1995)

Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP: Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87:1549-1555 (1996)

Li R, Yerganian G, Duesberg P, Krämer A, Willer A, Rausch C, Hehlmann R: Aneuploidy Correlated 100% with Chemical Transformation of Chinese Hamster Cells. Proc Natl Acad Sci USA 94:14506-14511 (1997)

Duesberg P, Rausch C, Rasnick D, Hehlmann R: Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A 95:13692-13697 (1998)

Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski PA, Horowitz MM, and the German CML Study Group: Survival with Bone Marrow Transplantation Versus Hydroxyurea or Interferon for Chronic Myelogenous Leukemia (CML). Blood 91:1810-1819 (1998)

Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J, Alimena G, Steegmann JL, Ansari H: A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90:850-858 (1998)

Hehlmann R: A chance of cure for every patient with CML? N Engl J Med 338:980-982 (1998)

Lengfelder E, Hochhaus A, Kronawitter U, Höche D, Queißer W, Jahn-Eder M, Burkhardt R, Reiter A, Ansari H, Hehlmann R: Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages. Br J Haematol 100:15-23 (1998)

Seifarth W, Baust C, Murr A, Skladny H, Krieg-Schneider F, Blusch J, Werner T, Hehlmann R, Leib-Mösch C: Proviral structure, chromosomal location and expression of HERV-K-T47D, a novel human endogenous retrovirus derived from T47D particles. J Virol 72:8384-8391 (1998)

Hehlmann R, Essex M: Comparative research in leukemia and related diseases. An introduction to a scientific approach. Leukemia 13:S19-S28 (1999) 

Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, Siegert W, Finke J, Ehninger G, Holler E, Berger U, Pfirrmann M, Muth A, Zander A, Fauser AA, Heyll A, Nerl C, Hossfeld DK, Löffler H, Pralle H, Queißer W, Tobler A, for the German CML-Study Group and the SAKK: Interferon alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 94:3668-3677 (1999) 

Krämer A, Hörner S, Willer A, Frühauf S, Hochhaus A, Hallek M, Hehlmann R: Adhesion to fibronectin stimulates proliferation of wild type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci USA 96:2087-2092 (1999) 

Silver RT, Woolf SH, Hehlmann R, Appelbaum FA, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S: Review: An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517-1536 (1999) 

Baust C, Seifarth W, Germaier H, Hehlmann R, Leib-Mösch C: HERV-K-T47D-related long terminal repeats mediate polyadenylation of cellular transcripts. Genomics 66:98-103 (2000)

Duesberg P, Stindl R, Hehlmann R: Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 97:14295-14300 (2000)

Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP for the German CML Study Group and the UK MRC CML Study Group: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95:62-66 (2000)

Baust C, Seifarth W, Schon U, Hehlmann R, Leib-Mösch C: Nucleotide functional activity of HERV-K-T47D-related long terminal repeats. Virology 283:262-72 (2001)

Duesberg P, Stindl R, Hehlmann R: Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci USA 98:11283-8 (2001)

Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NCP, Linkesch W, Druker BJ, Hehlmann R: Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a (2001)

Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A: Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood 97:3648-50 (2001)

Buchheidt D, Baust C, Skladny H, Baldus M, Brauninger S, Hehlmann R: Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 116:803-11 (2002)

Fabarius A, Willer A, Yerganian G, Hehlmann R, Duesberg P: Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. Proc Natl Acad Sci USA. 99:6778-83 (2002)

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196 (2002)

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A: Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16:1579-83 (2002)

Berger U, Engelich G, Maywald O, Pfirrmann M, Hochhaus A, Reiter A, Metzgeroth G, Gnad U, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R and the German CML-Study Group: Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia 17:1820-6 (2003)

Büsche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A: Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia 17:2444-53 (2003)

Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Müller MC, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A: Interferon alpha, but not the ABL-kinase inhibitor imatinib (STI571) induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259-264 (2003)

Fabarius A, Hehlmann R, Duesberg PH: Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 143:59-72 (2003)

Hehlmann R: Current CML therapy: progress and dilemma. Leukemia 17:1010-1012 (2003)

Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H: Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529-1537 (2003)

Reiter A, Saussele S, Grimwade D, Wiemels JL, Segal MR, Lafage-Pochitaloff M, Walz C, Weisser A, Hochhaus A, Willer A, Reichert A, Büchner T, Lengfelder E, Hehlmann R, Cross NC: Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia. Genes Chromosomes Cancer 36:175-88 (2003)

Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Schwerdtfeger R, Cornely O, Wilhelm S, Reuter S, Kern WV, Südhoff T, Mörz H, Hehlmann R: Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 125:196-202 (2004)

Hehlmann R, Berger U, Aul C, Büchner T, Döhner H, Ehninger G, Ganser A, Gökbuget N, Hoelzer D, Überla K, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann W, Ottmann OG, Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Böhme A, Harrison-Neu E, Griesshammer M, Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B, Niederwieser D, Heil G, Müller T, Hasford J: The German competence network 'Acute and chronic leukemias'. Leukemia 18:665-9 (2004)

Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R; German CML-Study Group: Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 19:984-9 (2005)

Hehlmann R, Berger U, Hochhaus A: Chronic myeloid leukemia: a model for oncology. Ann Hematol 84:487-497 (2005)

Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168 (2005)

Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center. Cancer 103:1659-69 (2005)

Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 65:2662-7 (2005)

zurück